ArticleFrontiers in cardiovascular medicine2026
Analysis of the efficacy of transesophageal atrial pacing in the treatment of supraventricular tachycardia in newborns.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe and explore the therapeutic value of transesophageal atrial pacing (TEAP) for supraventricular tachycardia in newborns. Methods: Clinical data from 22 cases (15 males, 7 females) at Shanghai Children's Hospital (2015-2025) were retrospectively analyzed to evaluate the efficacy of TEAP. Results: Surface ECGs demonstrated paroxysmal SVT and type I atrial flutter in 11 cases respectively, with 8 patients having heart failure. After inserting the esophageal electrode catheter, transesophageal electrocardiography confirmed Atrioventricular Reentrant Tachycardia (AVRT) in 9 of 11 SVT cases; TEAP successfully terminated tachycardia in 7 (77.8% success). In a case, pulse stimulation had not yet been administered, a declining trend in blood pressure was observed, which necessitated electrical cardioversion. Another with short paroxysms post-TEAP was maintained on oral medication. Two cases of atrial tachycardia confirmed by transesophageal electrocardiogram did not respond to TEAP. Among 11 type I atrial flutter cases, TEAP restored sinus rhythm in 9 (81.8% success); one had intermittent short paroxysms and one showed reduced atrioventricular conduction, both switched to oral drugs. Conclusion: TEAP is a relatively safe and effective acute treatment for reentrant SVT (AVRT, AFL) when medication cannot promptly and effectively terminate tachycardia, particularly for patients with heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.